Tuesday, November 26, 2019 9:27:52 AM
Download as PDFNOVEMBER 26, 2019 8:00AM EST
HOUSTON, Nov. 26, 2019 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("Company"), a biotechnology company specializing in the development of novel treatments for brain tumors, entered into a sublicense agreement with WPD Pharmaceuticals ("WPD"), a Polish corporation partially owned and controlled by Dr. Waldemar Priebe, the founder of the Company. The agreement grants WPD patent rights to research and develop, and manufacture or sell Berubicin in a limited territory comprised mainly of Eastern Europe and Central Asia. The Company is entitled to a 1% royalty on all commercial sales of Berubicin in these licensed territories.
As part of the agreement, WPD committed to a $2.0 million minimum expenditure on the development, testing, regulatory approval, and commercialization of Berubicin during the three year term of the agreement, which ends in August 2021. WPD plans to implement a multicenter pediatric Phase I clinical trial to determine maximum tolerated dose, and to determine the efficacy of Berubicin in Phase IB and II clinical trials in adults. WPD also plans to conduct preclinical tests to determine the prospective use of Berubicin with temozolomide and with other compounds as anticancer drugs.
"We were extremely excited to enter into an agreement with WPD and to further explore the potential of Berubicin as an anthracycline internationally," commented CEO of CNS, John M. Climaco. "Our agreement with WPD is truly a testament to our unrelenting commitment to pursuing treatments for glioblastoma around the world."
Recent CNSP News
- Form 8-K - Current report • Edgar (US Regulatory) • 09/18/2024 08:30:08 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/12/2024 12:58:31 PM
- IBN Announces Latest Episode of The BioMedWire Podcast featuring John Climaco, CEO of CNS Pharmaceuticals Inc. • GlobeNewswire Inc. • 09/03/2024 12:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2024 09:22:52 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/07/2024 11:30:09 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/06/2024 09:11:50 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 08/06/2024 08:53:41 PM
- Form SC 13D - General Statement of Acquisition of Beneficial Ownership • Edgar (US Regulatory) • 08/02/2024 08:11:48 PM
- Form RW - Registration Withdrawal Request • Edgar (US Regulatory) • 07/31/2024 04:32:30 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 07/30/2024 09:15:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/30/2024 09:13:02 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/30/2024 11:00:51 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/26/2024 12:30:04 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/26/2024 12:00:11 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/24/2024 01:30:08 PM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 07/19/2024 09:12:54 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 07/12/2024 08:30:47 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/09/2024 03:25:14 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 06/17/2024 03:17:39 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/14/2024 09:25:33 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/05/2024 09:00:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/16/2024 02:56:04 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/15/2024 09:00:33 PM
FEATURED Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • Sep 24, 2024 8:50 AM
FEATURED Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM